NYSE$INSP
Inspire Medical Systems Inc. · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported a strong third quarter with significant revenue growth and improved operating leverage.
Inspire Medical Systems reported a 33% year-over-year revenue increase to $203.2 million and earnings per share of $0.60 in the third quarter of 2024. The company is increasing its full year revenue guidance to $793 million to $798 million and raising its full year earnings per share guidance to $1.20 to $1.40.
- Generated revenue of $203.2 million, a 33% increase year-over-year.
- Achieved a gross margin of 84.1%.
- Reported operating income of $14.3 million and earnings per share of $0.60.
- Activated 66 new U.S. centers, bringing the total to 1,371.
Headline financials
Revenue & EPS history
Inspire · Revenue · Quarterly
$203M
Forward guidance
Inspire is increasing its full year 2024 revenue guidance to between $793 million to $798 million and increasing diluted net income per share guidance for the full year 2024 to between $1.20 to $1.40.
Tailwinds
- Full year 2024 revenue guidance increased to $793 million - $798 million.
- Full year 2024 gross margin guidance maintained at 83% - 85%.
- Full year 2024 diluted net income per share guidance increased to $1.20 - $1.40.
- Guidance relating to the opening of new U.S. medical centers maintained at 52 to 56 per quarter.
- Guidance of 12 to 14 new U.S. territories for the fourth quarter of 2024 maintained.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+2.4%
Avg return
Earnings day
+0.8%
Avg return
5 days after
+3.3%
Avg return
30 days after
69%
22 / 32 earnings
Positive
+34.4%
Q3 2020
Best reaction
-34.9%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -12.2% | -19.2% | -23.1% | |
| Q4 2025 | -12.5% | -11.5% | -14.1% | |
| Q3 2025 | +15.6% | +11.0% | +90.0% | |
| Q1 2025 | +1.6% | -4.7% | -14.4% | |
| Q4 2024 | +1.7% | +2.6% | -12.2% | |
| Q3 2024 | +4.3% | +3.1% | +3.3% | |
| Q2 2024 | +29.5% | +32.8% | +35.6% | |
| Q1 2024 | -34.9% | -33.1% | -37.7% | |
| Q4 2023 | -6.5% | -9.8% | -4.8% | |
| Q3 2023 | -20.9% | -23.5% | -2.1% | |
| Q2 2023 | -3.5% | -3.7% | -21.2% | |
| Q1 2023 | +5.0% | +5.8% | +15.3% | |
| Q4 2022 | +9.7% | +7.9% | -0.4% | |
| Q3 2022 | +6.0% | +6.4% | +22.9% | |
| Q2 2022 | +4.4% | +4.0% | -11.0% | |
| Q1 2022 | -4.5% | -19.8% | -14.4% | |
| Q4 2021 | +5.4% | +0.6% | -1.4% | |
| Q3 2021 | +1.3% | +4.1% | -16.0% | |
| Q2 2021 | +12.9% | +14.4% | +26.1% | |
| Q1 2021 | -16.0% | -17.4% | -29.6% | |
| Q4 2020 | +3.4% | +4.1% | -11.4% | |
| Q3 2020 | +34.4% | +40.7% | +60.3% | |
| Q2 2020 | +7.4% | +3.5% | +17.9% | |
| Q1 2020 | +3.7% | +6.2% | +26.1% | |
| Q4 2019 | +6.4% | +7.7% | -27.2% | |
| Q3 2019 | +4.3% | +4.8% | +21.7% | |
| Q2 2019 | +4.5% | +1.9% | +7.3% | |
| Q1 2019 | -2.5% | -5.7% | -0.6% | |
| Q4 2018 | +5.4% | +5.0% | -4.5% | |
| Q3 2018 | +15.4% | +1.8% | -9.9% | |
| Q2 2018 | -1.8% | -0.1% | +15.6% | |
| Q1 2018 | +10.0% | +6.4% | +20.5% | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro